12h agoBarron'sBEARISH 34General
Archived explainer. For the current picture see today's ARWR page.
Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Down Today?
By the Top Tier Newswire AI Desk · September 16, 2026 at 12:09 AM ET · reviewed against 4 wire stories
ARROWHEAD PHARMACEUT (ARWR) is down -12.40% in the latest session. Our newswire has captured 4 stories on ARWR across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ARWR stock is down today
Arrowhead Pharmaceuticals (ARWR) fell 12.40% to $70.67 in a single session, marking one of the largest declines in the sector. The drop came despite the release of positive interim clinical data for its dual-functional RNAi therapeutic targeting mixed hyperlipidemia. The stock's sharp move reflects a "sell the news" reaction from investors, who may have already priced in the data or are reacting to broader market conditions and internal factors.
What Happened
Arrowhead Pharmaceuticals announced interim topline data from its Phase 1/2a study, showing mean maximal reductions of 88% in APOC3, 54% in LDL-C, and 73% in triglycerides. These results highlight the potential of its first dual-functional RNAi therapeutic. However, the market responded negatively, with the stock falling to its worst day in over a year. The decline followed a period of strong performance, with the stock reaching a 52-week high near $95 in July. Two directors, Perry Michael S and Olukotun Adeoye Y, sold shares on August 18, 2026, adding to investor caution. Additionally, the stock has declined 14.5% over the past eight sessions, moving from $85.40 to $73.04.
What The Data Shows
The stock has printed 64 fresh 52-week lows on September 15, 2026, while also hitting two 52-week highs, indicating a volatile price trend. Over the past 30 days, sentiment has deteriorated from an average of 58/100 to 51/100. The company has a market cap of $11.7B and remains unprofitable, with a trailing twelve-month EPS of -2.28 and a net margin of -47.8%. Despite recent analyst optimism, including a "Buy" rating from Citigroup with a $108 price target, the stock's fundamentals and recent insider selling have contributed to the downward pressure.
What To Watch
The stock is scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Investors should monitor the presentation for further insights into the drug's development and the company's strategic direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ARWR by the numbers
Last: $70.67Session: -12.40%7 sessions: -14.48%Coverage: 4 stories / 4 sourcesAI sentiment: 49/100 (mixed)Mkt cap: $11.7B52w: $28.12 to $95.49
The headlines behind the move
13h agoStocktwits NewsBEARISH 38General
ARWR Stock On Track For Worst Day In Over A Year Despite Positive Early-Stage Data For Cholesterol Drug — Retail Dismisses ‘Sell The News’ Reaction
ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.
14h agoSeeking AlphaBULLISH 56General
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsDr.
21h agoStockTitanBULLISH 67Product/PR
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
The Phase 1/2a study also found mean maximal reductions of 88% in APOC3, 54% in LDL-C and 73% in triglycerides; multiple-dose safety testing continues.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ARWR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ARWR move explainers: 2026-09-16 · 2026-09-15 · 2026-09-08 · 2026-08-31